Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Project description:The biotransformation of hexavalent chromium [Cr(VI)] via Cr(VI)-reducing microorganisms is considered an ecofriendly approach to detoxify Cr(VI). A new Cr(VI)-reducing bacterium named Microbacterium sp. QH-2 was isolated in this study. Scanning electron microscopy (SEM) images showed protrusions on the bacterial surface of strain QH-2 after an 18 h incubation in media under 10 mM Cr(VI) treatment. Results of the experiments on the capacity of reducing Cr(VI) indicated that strain QH-2 could reduce 100% Cr(VI) less than 48-96 h. When media with 4 mM Cr(VI) were incubated, the fastest reduction rate of strain QH-2 could come up to 2.17 mg/L Cr(VI) h-1. Furthermore, strain QH-2 could reduce Cr(VI) over the pH between 7 and 10. The optimum pH to reduce Cr(VI) by strain QH-2 was 9. Strain QH-2 also exhibited a relatively high tolerance even to 20 mM Cr(VI). These results declared that strain QH-2 had the potential to detoxify Cr(VI) in the Cr(VI)-contaminated soil or effluent.
